中新网上海10月5日电 索诺瓦集团中国区总经理方芳5日在此间接受中新网记者专访时表示，索诺瓦集 团希望加速在中国引入新产品，尽可能与全球同步；加速前沿产品的国产化落地；同时，加速在中国全 听力领域的临床研究和探索。 "索诺瓦集团不仅希望将最先进的技术和产品引入中国，也希望用在华获得的研发成果反哺全球。"她 说，"我们希望借助中国临床研究团队的智慧，研发出适应中国市场需求的产品。" 芳芳认为，在中国，听力健康的意识远远落后于视力健康的意识。吴佩娜亦表示，在临床上，老人对耳 聋有很多误解。有的老人听损已达到重度、极重度，家人和他说话像吵架一样大声。老人却觉得自己还 可以听到声音，就认为没有聋。据了解，既往，全国只有几个领先的耳鼻喉科中心可以开展人工耳蜗植 入手术。现在，全国有更多医院开展人工耳蜗的植入。这需要更多医生具备扎实的操作技能。 "对于成年人，我们希望其植入人工耳蜗后获得良好的听力效果。这除了电极的选择，还需要医生的高 水平操作。"吴佩娜直言，一些曾体验过美妙声音的成年人会对人工耳蜗植入后的效果有更高期待。因 此，在完成人工耳蜗手术时，尤其在植入电极过程中，医生需要更精细、更规范的操作。 "目前人工耳蜗植 ...

值得关注的是，国家药监局最新批准发布了《采用脑机接口技术的医疗器械术语》医疗器械行业标准。 这是中国第一项脑机接口医疗器械标准，为脑机接口医疗器械产业高质量发展奠定基础。该标准将于 2026年1月1日正式实施。 脑动极光-B(06681)拉升逾14%，截至发稿，涨14.08%，报8.5港元，成交额3.11亿港元。 消息面上，近日，工业和信息化部部长李乐成在第25届中国国际工业博览会开幕式上致辞时表示，要实 施培育新兴产业打造新动能行动，统筹技术创新、规模化发展和应用场景建设，加快打造一批新兴支柱 产业；建立未来产业投入增长机制，加强前沿技术研发和应用推广，开辟人形机器人、脑机接口、元宇 宙、量子信息等新赛道，创建一批未来产业先导区。 据了解，脑动极光核心产品是脑功能信息管理平台软件系统，为中国首款获得监管批准的认知障碍数字 疗法产品。公司将脑科学与人工智能技术相结合，其核心产品系统具备虚拟人技术和AI技术等独特技 术优势。作为中国首家开发出针对认知障碍的医疗级数字疗法产品的公司，具有先发优势。其核心产品 已纳入中国30个省份的省级医保报销目录，且公司已成功帮助超过120家医院在中国建立认知中心，其 中包括多家 ...

Group 1 - The core concept of the article revolves around the innovative digital therapy solutions provided by Yuan Yikang Health Technology Co., Ltd., which utilizes virtual reality to treat phobias and cognitive disorders [1][4] - Yuan Yikang's therapy involves immersive experiences where patients wear headsets to simulate high-altitude environments, gradually increasing their tolerance to heights [2][3] - The company integrates XR (Extended Reality) and AI technology to offer personalized treatment plans, enhancing diagnostic efficiency and resource management in healthcare [3][4] Group 2 - The digital therapy industry in Hainan has gained significant attention, with the province implementing over 30 supportive policies since 2022 to promote the sector [4] - By July 2025, Hainan is expected to host 73 digital therapy companies, with many being leading firms in their respective niches, particularly within the Hainan Eco-Software Park [4] - Yuan Yikang's cognitive function assessment and training software has received multiple certifications, including EU CE and UK MHRA, and is being marketed in Southeast Asia and Europe [4] Group 3 - The potential applications of digital therapy extend beyond phobias, exploring treatments for PTSD, addiction, autism, and cognitive recovery in elderly patients [5]

Core Insights - The integration of VR and AI in healthcare is leading to a quiet revolution, redefining the boundaries of health and wellness, with applications ranging from pain relief to treating Alzheimer's disease [1][12] - Walter Greenleaf, a leading expert in VR and digital health, emphasizes the importance of translating laboratory results into market applications to aid startups in scaling their innovations [2] - Immersive therapies are emerging as a new class of treatment, utilizing VR and AR to help patients overcome psychological barriers in a safe environment [4] Group 1: Immersive Therapy Applications - Immersive therapies are being used for PTSD treatment, addiction recovery, and social training for children with autism, showcasing the potential of VR and AR as "second-generation drugs" [4] - The concept of "on-demand experiences" allows patients to enter virtual worlds that facilitate gradual exposure to their fears and anxieties [4] Group 2: Aging Population and Investment Opportunities - By 2050, one in six people will be over 65, highlighting the need for solutions that maintain brain vitality as longevity increases [6] - The focus on brain health is becoming a more critical investment topic than wealth accumulation, with sleep being identified as a key factor [6] Group 3: China's Opportunities in AI and Healthcare - China possesses significant advantages in AI and healthcare technology, particularly in precision medicine and data application, positioning it for rapid advancements in these fields [8] Group 4: Digital Therapeutics and Regulatory Changes - The FDA has established a new category for "software as a medical device," allowing for the prescription of software, indicating a shift towards mainstream acceptance of digital therapies [10] - The next 5-10 years are expected to see the scaling of immersive medical applications within healthcare systems [10]

Core Viewpoint - The article discusses the transformative impact of immersive technologies like VR and AI on healthcare, highlighting their potential to redefine health boundaries and address various medical conditions, thus opening up opportunities in the trillion-dollar silver economy [1][5]. Group 1: Immersive Therapy - Immersive therapy is being utilized for various treatments, including PTSD, addiction, and social training for children with autism, positioning VR and AR as "second-generation drugs" [8]. - Patients can gradually overcome psychological barriers in a safe environment through virtual scenarios and real-time AI adjustments [8][9]. Group 2: Aging and Health - By 2050, one in six people will be over 65, making brain health a critical investment topic, as longevity does not equate to sustained brain vitality [11]. - Sleep is identified as a key factor in maintaining brain health, with genetics serving as a reminder to focus on cognitive well-being [11]. Group 3: Opportunities in China - China possesses significant latecomer advantages in AI and medical technology, particularly in precision medicine and data application [14]. - The country is poised to rapidly advance in these fields, indicating a strong potential for growth and innovation [14]. Group 4: Digital Therapeutics - The FDA has established a new category for "software as a medical device," allowing doctors to prescribe software, indicating that digital therapies are becoming mainstream [17]. - Immersive medical applications are expected to enter a phase of large-scale implementation within the next 5-10 years [18].

两说 Business Insights 当虚拟现实不再只是游戏，它能否成为改变医学未来的力量？从创伤治疗到神经康复，科技如何重 塑人类健康？在这场技术与医疗的博弈中，谁能掌握主动权？斯坦福大学虚拟人机交互实验室神经科学 家、虚拟现实与数字健康专家沃尔特·格林利夫博士，与第一财经主持人尹凡深入探讨了沉浸式技术如 何重塑医疗健康产业，从认知逆转到数字疗法，从心理健康到老龄化社会的全球挑战。 更多精彩内容，敬请关注9月24日周三晚22:30 东方卫视 《两说》节目， 第一财经 9月27日周六晚22:00 播 出。 尹 凡 第一财经主持人 沃尔特·格林利夫 斯坦福大学虚拟人机交互实验室神经科学家 虚拟现实与数字健康专家 Business Ins 09\24 22:30 09\27 22:00 东方卫视首播 第一财经播出 ...

每年9月为世界阿尔茨海默病月，9月21日为世界阿尔茨海默病日。9月19日，2025年世界阿尔茨海默病 月主题宣传活动启动仪式在北京举行。记者了解到，北京市卫健委正会同相关部门研究制定应对老年期 痴呆北京行动方案，健全北京市老年期痴呆防控体系，预防和延缓老年期痴呆发生发展。 从2019年开始，北京为65岁及以上常住老年人和50岁及以上有糖尿病、高血压、脑卒中病史或近一年主 诉记忆力下降情况的居民提供免费脑健康体检（认知功能筛查）。2025年，脑健康体检项目纳入市政府 民生实事项目。 北京计划利用3至5年时间，依托老年期痴呆全病程服务协作网，逐步完善分层分类管理措施。对认知功 能初筛正常的老年人提供健康教育服务，对初筛阳性的作为重点人群开展认知功能评估，评估结果异常 的，指导其到有条件的医疗机构就诊。到2030年，认知功能初筛阳性人群干预指导率不低于80%，疑似 认知障碍人群就诊率不低于50%。同时，组织开展"黄手环"行动，向有需求的老年人免费发放定位手环 等防走失用品，减少痴呆老年人走失风险。加强心理援助热线建设和心理健康促进工作。 今年将建设记忆门诊不少于20家 目前，北京市卫健委正会同相关部门研究制定应对老 ...

Group 1 - The market perceives that companies listed on the Hong Kong stock market benefit from being included in the Hong Kong Stock Connect, as it attracts southbound capital and enhances company visibility [1] - Brain动极光-B (06681.HK) experienced a significant price increase, rising by 32% last Friday and peaking at over 80% before a notable pullback, ultimately trading at HKD 10.4, reflecting a nearly 40% increase [1] - Since entering the Hong Kong Stock Connect, Brain动极光-B has seen its stock price nearly double, with a peak increase exceeding 100% within a week [1] Group 2 - Brain动极光 is the first Chinese company to combine brain science with advanced artificial intelligence to develop medical-grade digital therapy products for cognitive impairments [3] - The company's product pipeline addresses a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental disorders, and developmental defects in children [3] - In the first half of this year, Brain动极光 reported revenue of RMB 100 million, marking a year-on-year growth of 92.82% [3] Group 3 - Other stocks that entered the Hong Kong Stock Connect on September 8 also experienced significant price increases, such as药捷安康-B (02617.HK) with a cumulative rise of over 220% and映恩生物-B (09606.HK) with a cumulative rise of over 30% [3]

Core Insights - Medical technology company Yidu Tech (02158) saw its stock rise over 5%, currently trading at 6.65 HKD with a transaction volume of 69.47 million HKD [1] Group 1: Product Development and Innovations - Yidu Tech, in collaboration with Guangdong Medical University Affiliated Hospital, launched the "Multimodal Disease Database for Vascular Diseases" and "Meiyi Intelligent Body" at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association [1] - The "Meiyi Intelligent Body" serves as a core technology platform, marking Yidu Tech's first application of its large model in the medical aesthetics field [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Tech presented its achievements in the "2+3" diabetes management project in Hainan, highlighting its role as an AI medical enterprise [1] - Since the pilot program began in 2023, Yidu Tech has collaborated closely with Ling Shui County, achieving a 99.09% inclusion rate of managed patients into systematic care, with fasting blood glucose and glycated hemoglobin compliance rates improving by 18.63% and 4.68%, respectively, surpassing the provincial average [1] - Following Ling Shui, the company plans to extend its AI medical innovations to cities such as Sanya, Wanning, Qionghai, and Wenchang, with an aim to expand digital therapy services for hypertension and other chronic diseases, targeting coverage for over 100,000 regional patients by 2025 [1]

Core Viewpoint - Yidu Technology (02158) has seen a stock price increase of over 5%, currently trading at 6.65 HKD, with a transaction volume of 69.47 million HKD, following the announcement of its collaboration with Guangdong Medical University Affiliated Hospital on a specialized database for vascular diseases and the "Meiyi Intelligent Body" [1] Group 1: Product Development and Innovation - The "Meiyi Intelligent Body," developed in collaboration with Guangdong Medical University, represents Yidu Technology's first application of its large model in the medical aesthetics field [1] - The company showcased its technological advancements at the 2025 Academic Annual Meeting of the Guangdong Provincial Hospital Association's Plastic Surgery Professional Committee [1] Group 2: Digital Health Initiatives - At the 2025 Digital Therapy Conference, Yidu Technology reported its involvement in the "2+3" diabetes management project in Hainan, highlighting its achievements since the pilot program began in 2023 [1] - The collaboration with Ling Shui County has resulted in 99.09% of managed patients being integrated into a systematic care program, with significant improvements in fasting blood glucose and glycated hemoglobin levels, increasing by 18.63% and 4.68% respectively, surpassing the provincial average [1] - The company plans to expand its AI healthcare innovations to other cities such as Sanya, Wanning, Qionghai, and Wenchang, and aims to extend digital therapy services to more chronic diseases like hypertension, targeting coverage for over 100,000 regional patients by 2025 [1]